Esteve to acquire TerSera therapeutics business unit

Spanish privately-held pharma company entered into an agreement to acquire USA-based TerSera's Infusion Specialty Therapies Business Unit (IST). This strategic acquisition enables Esteve to expand its US presence, with two highly specialized on-market assets and a dedicated team of sales, marketing and medical professionals.

TerSera's IST business unit includes two specialty medications, Prialt (ziconotide intrathecal infusion) and Quzyttir (cetirizine hydrochloride injection). Prialt is the only Food and Drug Administration (FDA)-approved, non-opioid agent indicated for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Prialt is currently marketed in Europe by Esteve. Quzyttir is the first and only injectable second-generation H1 antihistamine approved by the FDA for the treatment of acute urticaria in adults and children six months of age and older.

With this transaction, Esteve will obtain worldwide rights for Quzyttir in all territories (except for China) and consolidates its rights for Prialt worldwide.Financial terms of the deal were not disclosed.